VERACYTE INC

Veracyte board member Jens Holstein’s Rule 10b5‑1 trades show disciplined, profit‑taking in a bullish market—insider activity that signals portfolio rebalancing, not a loss of confidence.

Holstein Jens sells 5,000 Veracyte shares at $41, showing routine portfolio rebalancing amid the company’s Convergent Genomics merger and promising urine‑based assay expansion.